Bank Julius Baer & Co
CYCN icon

Bank Julius Baer & Co’s Cyclerion Therapeutics CYCN Stock Holding History

Bank Julius Baer & Co’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-600
Closed -$33K – 833
2021
Q1 		$33K Sell
600
-299
-33% -$22.5K ﹤0.01% 710
2020
Q4 		$55K Buy
+899
New +$61.3K ﹤0.01% 672
2020
Q2 		– Sell
-698
Closed -$37K – 696
2020
Q1 		$37K Buy
+698
New +$49.8K ﹤0.01% 557

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank Julius Baer & Co's CYCN Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of Cyclerion Therapeutics (CYCN) in Q2 2021, closing a stake of 600 shares — an estimated $33K sold.

Bank Julius Baer & Co first reported a position in CYCN in Q1 2020 and held it in 3 quarters. The position peaked at $55K in Q4 2020. 67 funds tracked by Wall St. Rank hold CYCN as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining Cyclerion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 600 Cyclerion Therapeutics shares in Q2 2021, an estimated $33K.
  • Bank Julius Baer & Co first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 3 quarters.
  • Bank Julius Baer & Co's Cyclerion Therapeutics position peaked at $55K in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.